Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance

Cell Death and Differentiation

Volumn 5, Issue 5, 1998, Pages 390-400

  Ségal Bendirdjian, Evelyne ^a,b   Mannone, Lionel ^a   Jacquemin Sablon, Alain ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Apoptosis; Cisplatin resistance; Endonuclease; L1210 leukemia cells; p21; p53

Indexed keywords

CALCIUM ION; CISPLATIN; ENDONUCLEASE; ETOPOSIDE; MAGNESIUM ION; PROTEIN P53;

ADAPTATION; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; CROSS RESISTANCE; DNA DAMAGE; DRUG RESISTANCE; ENZYME ACTIVITY; GENETIC DISORDER; LEUKEMIA CELL LINE; MOLECULAR GENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; MURINAE;

EID: 0031820832     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400357     Document Type: Article

References (40)

1. Agarwal ML, Agarwal A Taylor WR and Stark GR (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl Acad. USA 92: 8493-8497
2. Andrews PA and Howell SB (1990) Cellular pharmacology of cisplatin. perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43
3. Arends MJ, Morris RG and Wyllie AH (1990) Apoptosis. The role of the endonuclease. Am. J. Pathol 136 593-608
4. Barry MA, Behnke CA and Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40. 2353-2362
5. Biard DSF, Martin M, Le Rhum Y, Duthu A, Lefaix JL, May E and May P (1994) Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res. 54: 3361-3364
6. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B and Kaye SB (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer 55. 678-684
7. Clarke AR Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond ) 362. 849-352
8. Dive C and Hickman JA (1991) Drug-target interactions: only the first step in the commitment to a programmed cell death Br. J. Cancer 64: 192-196
9. Eastman A and Schulte N (1988) Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27: 4730-4734
10. 1 arrest and apoptosis. Cancer Res. 54: 1169-1174
11. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC and Young LS (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl2. Oncogene 11: 1217-1228
12. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW and O'Connor PM (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54: 5824-5830
13. Gately DP and Howell SB (1993) Cellular accumulation of the anticancer agent, cisplatin: a review. Br. J. Cancer 67: 1171-1175
14. Griffiths SD, Clarke AR, Healy LE, Ross G, Ford AM, Hooper ML, Wyllie AH, Greaves M (1997) Absence of p53 permits propagation of mutant cells following genotoxic damage. Oncogene 14: 523-531
15. Hamilton TC, O'Dwyer PJ and Ozols RF (1993) Platinum analogues in preclinical and clinical development. Curr. Opin. Oncol. 5: 1010-1016
16. Hawkins DS, Demers GW and Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56: 892-898
17. Hoffman B and Lieberman DA (1994) Molecular controls of apoptosis: differentiation/ growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators Oncogene 9: 1907-1812
18. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311
19. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad Sci. USA 89: 7491-7495
20. Lai GM, Ozols RF, Smyth JF, Young RC and Hamilton TC (1988) Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem. Pharmacol. 37: 4597-4600
21. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935
22. Loehrer PJ and Einhorn LH (1984) Cisplatin Ann. Intern Med. 100: 704-713
23. Lowe SW, Schmitt EM, Smith SW, Osbome BA and Jacks T (1993a) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.) 362 847-849
24. Lowe SW, Ruley HE, Jacks T and Housman DE (1993b) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967
25. Miller SA, Dykes DD and Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acids Res. 16: 1215
26. Nelson WG and Kastan MB (1994) DNA strand breaks. the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol 14. 1815-1823
27. Nieto MA and Lopez-Rivas A (1989) IL-2 protects T lymphocytes from glucocorticoidinduced DNA fragmentation and cell death. J. Immunol. 143. 4166-4170
28. Oltvai ZN and Korsmeyer SJ (1994) Checkpoints of dueling dimers foil death wishes. Cell 79. 189-192
29. Oren M (1994) Relationship of p53 to the control of apoptotic cell death. Cancer Biol 5: 221-227
30. Ormerod MG, Orr RM and Peacock JH (1994) The role of apoptosis in cell killing by cisplatin: a flow cytometry study. Br J. Cancer 69: 93-100
31. Ormerod MG, O'Neill C, Robertson D, Kelland LR and Harrap KR (1996) cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. 37: 463-471.
32. Perego P, Giarola M, Righetti SC, Supino R, Casenni C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56: 556-562
33. Richon VM, Schulte N and Eastman A (1987) Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res 47. 2056-2061
34. Scanlon KJ and Kashani-Sabet M (1988) Elevated progression of thymidylate synthase cycle were denved from a L1210/0 parental cell line by progressive adaptation to increasing doses of cisplatin. Proc. Natl. Acad. Sci. USA 85: 650-653
35. Scheibani N, Jennerwein MM and Eastman A (1989) DNA repairin cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry 28. 3120-3124
36. Ségal-Bendirdjian E and Jacquemin-Sablon A (1995) Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp. Cell Res 218: 201-212
37. Sorenson CM, Barry MA and Eastman A (1990) Analysis of events associated with cell cycle arrest at G2 and cell death induced by cisplatin. J. Natl. Cancer Inst. 82: 749-745
38. Stewart N, Hicks GG, Paraskevas F and Mowat M (1995) Evidence for a second cell cycle block at G2/M by p53 Oncogene 10: 109-115
39. Tragnos F, Gong J, Ardelt B and Darzynkiewicz Z (1994) Effect of staurosporine on MOLT-4 cell progression through G2 and on cytokines. J. Cell. Physiol. 158 535-544
40. Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 183. 39-51